Huiyao Huang

Guangxi Medical University — China

Economics, Econometrics and Finance · Social Sciences

25h-index1.9kcitations124works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(34), Economic and Financial Impacts of Cancer(27), Global Cancer Incidence and Screening(20), Cancer Genomics and Diagnostics(14), Colorectal Cancer Screening and Detection(12)

Publications124 total

Toward phase contribution assessment in perioperative oncology: insights from NSCLC and a proposal for broader implementation
Military Medical Research·2025Open Access
A roadmap for personalized medicine: the findings of the IC2PerMed project
Frontiers in Medicine·2025Open Access
Insights into Support Systems for Orphan Drug Development: A Comparative Study
Therapeutic Innovation & Regulatory Science·2025
[Current management status of real-world studies in medical institutions in China].
PubMed·2025
Understanding the gap between expectations and reality in decentralized clinical trials
npj Digital Medicine·2025· 4 citedOpen Access
Risk-Based Local Radiation Therapy in Oligometastatic Non-small Cell Lung Cancer in the Era of Immunotherapy: A Multicentric Cohort Study
International Journal of Radiation Oncology*Biology*Physics·2025· 1 cited
Challenging go/no-go decision scenarios and design recommendations in phase II oncology trials
Journal of the National Cancer Center·2025Open Access
Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives
Medicine Plus·2025· 6 citedOpen Access
Evaluation of changes in objective visual quality based on tear film stability after SMILE surgery
Frontiers in Medicine·2025· 1 citedOpen Access
Expediting the integration of China into the global rare disease drug development and approval
Science Bulletin·2025
Risk prediction for recurrent pregnancy loss based on routine inspections in the first trimester of pregnancy, a retrospective study in China
Frontiers in Medicine·2025· 2 citedOpen Access
Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond
Cancer Communications·2025· 1 citedOpen Access
[Development of an evaluation indicator system for access to cancer screening services: a Delphi study].
PubMed·2025
Natural killer cell therapy: the key to tackle the bottleneck of cell therapies against solid tumor?
Science Bulletin·2025· 5 citedOpen Access
Trends of drug licensing in China: From bring-in to go-global
Pharmacological Research·2024· 5 citedOpen Access
[International comparison and assessment of the quality of drug clinical trial implementation in China based on scientific regulatory system].
PubMed·2024· 2 cited
[Expedited program and utilization for anticancer drug approval in China and the United States].
PubMed·2024· 2 cited
A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project 
2024Open Access
Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review
European Journal of Cancer·2024· 7 cited
Quantitative evaluation of the impact of relaxing eligibility criteria on the risk–benefit profile of drugs for lung cancer based on real‐world data
Thoracic Cancer·2024· 2 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Min Dai(26), Jufang Shi(21), Jiansong Ren(20), Jie He(18), Lanwei Guo(17), Ayan Mao(17), Shuhang Wang(16), Ning Li(16), Xianzhen Liao(16), Dawei Wu(15), Yuan Fang(13), Guoxiang Liu(13), Xiaojie Sun(13), Bingbing Song(13), Peian Lou(13), Hong Fang(13), Kai Zhang(12), Xiaohua Sun(12), Jinyi Zhou(12), Yana Bai(11)